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patients received medical services to the value of 927 million Euro or 14.2% of total 
reimbursed lump-sums (6.53 billion Euros) in Austria. 224 million Euros fall upon 
medical tumour therapy. With regard to monoclonal antibody therapies, 56 million 
Euros was refunded. ConClusions: The current development in modern cancer 
therapies leads to efficient treatment pathways expressed in higher survival rates, 
reduced hospital days and an improved quality-of-life.
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objeCtives: The objective of this project was to identify the treatment cost of 
malignant ascites from the Italian NHS perspective through a cost-analysis. Three 
reference centers in Italy contributed to this study during year 2012. Methods: 
Three centers (Scientific Institute of Romagna for Cancer Studies and Treatment-
I.R.S.T; Medical Oncology Unit of San Gerardo Hospital; Department of Gynecology 
of University Hospital Agostino Gemelli) were chosen due to the fact that they treat 
a representative sample of patients with malignant ascites in Italy. Each center 
was asked to complete three case report forms: the first identifying the costs for 
the pre-procedure diagnostic tests, the second identifying the specific procedure 
costs (paracentesis) and the third identifying the specific costs due to treatment of 
complications. All these reports had to be completed for the last 5 patients diag-
nosed with malignant ascites in order to prevent selection bias. A total cost for each 
patient was calculated by DRG analysis (standard cost – tariff). The DRG analysis 
assessed: day hospital, admission number, hospitalization, number of hospitaliza-
tion days, principal diagnosis, main procedure/intervention, number of paracentesis 
procedures performed on the same patient with the same diagnosis, DRG type, 
DRG code, refund value for day hospital/ refund value for ordinary hospitaliza-
tion. Results: The analysis shows an average cost of € 1,464.42 per patient with 
malignant ascites using the DRG reimbursement rate (minimum value: € 1,405.63; 
maximum value: € 1,525.37). Analysis using DRG with complications resulted in a 
mean value of € 1,524.84 (minimum value: € 1,429.69; maximum value: € 1,625.55). 
The key cost driver of malignant ascites treatment was the paracentesis proce-
dure. ConClusions: The economic impact of paracenteses is high, especially when 
procedures must be repeated. The reduction in the number of paracenteses could 
reduce the costs while improving the QoL of the patients.
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objeCtives: Colposcopy is an essential part of the screening process for the preven-
tion of cervical cancer by diagnosing and treating precancerous lesions known as 
cervical intra-epithelial neoplasia (CIN). The objective of this study was to assess 
the cost and health impact of using an electrical impedance spectroscopy (EIS) 
device to aid in the diagnosis of precancerous lesions compared to standard colpos-
copy. A threshold for the EIS device that resulted in a similar sensitivity and higher 
specificity than standard colposcopy was used. Methods: Two models to assess 
the cost and health impacts were developed; a short term model representing the 
initial colposcopy treatment pathway and a longer term Markov model that included 
colposcopy follow-up. Sensitivity and specificity of colposcopy were derived from 
the EpiCIN trial of the EIS device. Two referral thresholds were defined in the analy-
sis, the threshold for ‘See and Treat’ on colposcopic impression alone (CI) and a 
lower threshold for referral for biopsy to determine disease presence (DP) prior to 
treatment. Costs of colposcopy were estimated using data from Sheffield Teaching 
Hospitals. Different colposcopy clinic scenarios were modelled to represent the 
different ways colposcopy clinics manage patients. Health related quality of life 
(HRQoL) decrements were applied for colposcopy, biopsy and treatment. One-way 
sensitivity analyses were also conducted. Results: The analysis suggests that the 
use of the EIS device can result in fewer biopsies being taken, a reduction in over-
treatment with an associated small improvement in HRQoL, and a lower colposcopy 
cost per woman with CIN2+ treated for some colposcopy clinic scenarios. The results 
are sensitive to changes in colposcopy costs. ConClusions: The use of the EIS 
device with a higher specificity and similar sensitivity to standard colposcopy has 
the potential to lead to a reduction in the colposcopy cost per woman with CIN2+ 
treated for some clinic scenarios.
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objeCtives: To estimate the epidemiological and economic benefits of a quad-
rivalent HPV vaccination in girls and boys compared with vaccination only in girls 
in Spain. Methods: A population-based compartmental dynamic transmission 
model of HPV developed in the US was partially adapted to the Spanish setting 
updating epidemiological data of HPV related diseases, the vaccination coverage and 
direct costs of the diseases. The analysis was performed from the National Health 
System (NHS) perspective. The strategy of cervix cancer screening (CCS) and vac-
cination of only girls from 11 to 26 years (S1) was compared to CCS and vaccination 
of girls and boys from 11 to 26 years (S2) with the quadrivalent vaccine. Assuming 
the duration of protection against vaccine HPV types is lifetime, the results over a 
100-year time horizon, were estimated applying a discount of 3% on costs. In order 
PCN85
the ANAlysis of Costs ANd reimbursemeNts for luNg CANCer 
treAtmeNt iN the CzeCh rePubliC
Rogalewicz V.1, Simrova J.2, Vojtisek R.3, Bartak M.4
1Czech Technical University in Prague, Kladno, Czech Republic, 2University Hospital Plzen, Plzen 
- Lochotin, Czech Republic, 3University Hospital Plzen, Plzen - Lochotin, Czech Republic, 4J.E. 
Purkyně University, Usti nad Laben, Czech Republic
objeCtives: Lung cancer is the most frequently diagnosed oncologic disease world-
wide, annually diagnosed in nearly 1.4 million patients. In 2010, the incidence in 
men was 89.7 per hundred thousand people (in 1996, it was 102.3), while in women 
35.2 (against 22.9 in 1996). The severity of the disease is also reflected by the high 
mortality rate, which was 74.8 per hundred thousand people in men and 27.4 in 
women in 2010. Methods: Identifying the costs spent by a clinic/hospital is dif-
ficult in the Czech Republic, as the majority of hospitals work with cost related 
data in the “confidential” mode. The costs were estimated and verified based on 
expert opinions of pulmonologists, oncologists, head physicians and staff mem-
bers of technical and economic departments of five pneumo-oncologic centres and 
university hospitals in this study. Results: Totally 32 procedures (process maps) 
were identified in lung cancer treatment (10 in diagnostic, 22 in therapeutic pro-
cesses). Each procedure consists of diagnostics, therapy and subsequent monitor-
ing of patients. Costs for respective steps were assessed, and total costs for each 
therapeutic scheme were calculated. ConClusions: The calculations imply that 
treatment costs significantly differ depending on the selected diagnostic/ therapeu-
tic procedure. The setting of the reimbursement system generates different stimuli 
for providers who may reach both positive and negative balances. This fact may 
have an effect on economic results leading, in its consequence, to the preference 
of alternatives more suitable in terms of reimbursement regardless of the optimum 
procedures for a specific patient.
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objeCtives: To identify the chemotherapeutic treatment patterns and associated 
costs in patients with chronic lymphocytic leukemia (CLL) in the Private Healthcare 
System. Methods: A retrospective analysis of the Orizon database, containing 
inpatient and outpatient claims data of a pool of 102 HMOs (34% of the total Private 
Health System), from January 2009 to December 2012 was conducted. Eligibility cri-
teria were patients starting CLL (ICD-10 code C911) chemotherapy treatment from 
April 2009 to December 2012. This cohort of patients was followed until December 
2012, death or loss of follow-up. Chemotherapy regimens were identified based on 
the agents reported in the claims. Line of treatment was defined based on mean-
ingful interruption (> 6 months) and/or change in the chemotherapy regimen. 
Descriptive statistics (average, standard deviation and percentage) of treatment 
regimens, duration of treatment and costs were performed. Results: A total of 163 
patients representing 859 cycles of chemotherapy met eligibility criteria; 43.6% of 
the patients underwent more than one line of treatment, with total chemotherapy 
costs of R$84,979.63 per patient. The three most widely used chemotherapy regimen 
were: fludarabine, cyclofosfamide and rituximab (FCR), used in 81 (54.9%) patients 
with average treatment duration of 3.54 cycles and total costs of R$69,241.91 per 
patient; rituximab monotherapy, used in 44 (27.0%) patients, with average treatment 
duration of 4.05 cycles and total costs of R$59,543.12 per patient; and fludarabine 
and cyclofosfamide (FC), used in 19 (11.7%) patients, with average duration of 2.22 
cycles and total costs of R$7,075.95 per patient. Chemotherapy drugs accounted 
for 72.8% of the total costs, followed by other medicines (11%), disposable devices 
(5.5%) and hospital facility fees (5.0%). ConClusions: FCR is the standard of care 
in CLL patients treated in the Brazilian Private Health System, and almost half of 
the patients undergo more than one treatment line, creating a significant financial 
burden to private payers.
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objeCtives: In Austria, 38,000 people are yearly diagnosed with cancer, which 
is the world’s leading cause of death (Austria: 19,547), followed by heart disease 
and stroke. Advances in early detection, prevention and treatment have led to 
decreasing cancer death and more favorable outcomes. Moreover, significant 
increases in the cost of cancer care have come in parallel with these advances. 
The cost factor related to modern cancer treatment is increasingly a matter of 
debate. Hence, the aim of the analysis was to evaluate the cost of cancer expressed 
as reimbursed lump-sums of the DRG system, number of inpatients stays and 
Length-of-Stay (LOS) in the inpatient setting to bring more transparency in the 
discussion and bridge the information-gap. Methods: We performed a retrospec-
tive claim-based analysis with Austrian DRG-System (LKF Leistungsorientierte 
Krankenanstaltenfinanzierung) data. The DRG-System is based on ICD-10 codes. 
Payment consists of one or several case-based lump-sums. Our analysis included 
all cancer hospital admissions. The cost-evaluation is based on the refunded 
lump-sums of the DRG-System for the year 2011. Results: In 2011, 353,883 
inpatient stays with a diagnosis of cancer were monitored. Hospital stays due to 
cancer accounts for 14% of the entire inpatient stays in Austria. The average LOS 
in cancer patients was 4.35 days and was associated with average costs per stay 
of 3,730 Euros. Compared with the total number of admissions these numbers 
are below average (LOS: 5.43; costs per stay: 3,949 Euros). Furthermore, cancer 
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and complications, and patient co-morbidities. To assist in medical decision 
making from clinical and cost perspectives, we have developed a simulation 
model that synthesizes the evidence on NMIBC using the Archimedes Model 
platform. Methods: The NMIBC model consists of a patient generation compo-
nent in which virtual patients are constructed from SEER case listings; a natural 
history component that captures recurrence, progression, and bladder cancer 
mortality; a health care component that captures the effects of treatments, tests, 
and surveillance; and a cost component that tracks the costs relevant to bladder 
cancer care. Using this model, we performed a 5-year virtual clinical trial of 350 
NMIBC patients with demonstrated Bacillus Calmette-Guerin failure, randomized 
to either immediate cystectomy or conservative treatment with Mitomycin C 
(MMC) intravesical therapy. The model is integrated within the Archimedes Model 
platform, which captures the effects of both NMIBC and patient co-morbidities. 
This model, validated against 5 published studies, gives recurrence and progres-
sion rates within ±20% of published results. Results: The virtual clinical trial 
shows a 5-yr cystectomy rate of 51% in the MMC arm, with an average delay to 
cystectomy of 0.84 yr (median 0.44 yr). The immediate cystectomy arm saves 0.26 
life years (LY) and $5598 in total bladder cancer cost per patient compared to the 
MMC arm. ConClusions: We have constructed a dynamic, quantitative model of 
NMIBC that can predict clinical and economic outcomes and help optimize treat-
ment and surveillance guidelines. The virtual clinical trial quantifies LY and cost 
outcomes for immediate cystectomy versus conservative therapy, and provides a 
valuable tool for trial design and health economic analyses.
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objeCtives: To determine the cost-effectiveness of bendamustine-rituximab 
(Ben-R) versus fludarabine-rituximab (Fdb-R) in patients with iNHL who have pro-
gressed following treatment with rituximab or a rituximab-containing regimen in 
Colombia. Methods: An economic model was constructed from the Colombian 
health system perspective, with a 35-year (lifetime) horizon and a discount rate 
of 3%. The model included three health states, progression-free (PF), progressive 
disease (PD), and death, which were associated with utility weights of 0.81, 0.62 
and 0, respectively. Clinical inputs (response rates, Kaplan-Meier curves, haz-
ard ratios (HRs) and adverse event rates) were from the Stil NHL 2-2003 study. 
Resource use data were from interviews with three Colombian hematologists 
treating iNHL patients. Unit costs were from ISS and SISPRO report and were 
expressed as 2013 Colombian Pesos. Univariate and probabilistic sensitivity 
analyses were conducted to determine the key drivers of cost-effectiveness, and 
uncertainty around the results, respectively. Results: Total lifetime cost of Ben-R 
was $291,192,912 and total cost of Fdb-R was $260,463,392. Ben-R patients accrued 
more LYs (6.47 vs. 5.15), QALYs (4.66 vs. 3.56), and PFLYs (3.57 vs. 2.05) compared 
to Fdb-R patients. The ICERs were $23,286,360 (cost per LY), $27,956,124 (cost per 
QALY) and $20,259,063 (cost per PF LY). Univariate sensitivity analysis revealed that 
the ICER per LY was most sensitive to the PFS and OS HRs for Ben-R vs Fdb-R, the 
number of treatment cycles, and the cost of bendamustine. Probabilistic sensitiv-
ity analysis with 1,000 iterations estimated that Ben-R had a 52% chance of being 
cost-effective, compared to Fdb-R, at a willingness to pay (WTP) of $59M per LY, 
rising to a plateau of about 93% at a WTP of $175M and above. ConClusions: At 
a willingness-to-pay of $59M (three times the GDP per capita of Colombia) Ben-R 
is a cost-effective alternative to Fdb-R.
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objeCtives: Hexaminolevulinate (HAL) is an optical imaging agent used as an 
adjunct to white light cystoscopy (WLC) in the diagnosis and management of non-
muscle invasive bladder cancer (NMIBC). The objective of this study was to model 
the cost-effectiveness of HAL-assisted blue light cystoscopy (HAL-BLC) compared to 
WLC alone when used at initial transurethral resection of bladder tumours (TURB) 
from the perspective of the National Health Service (NHS) in England and Wales 
using available clinical data. Methods: A two-part model was developed to esti-
mate the incremental cost-effectiveness of HAL-BLC at initial TURB for patients 
positively diagnosed in the outpatient setting with NMIBC over a lifetime hori-
zon. This consisted of a short-term decision tree, which estimated the outcome 
of the outpatient diagnostic procedure and inpatient TURB, and a Markov cohort 
model, used to extrapolate long term outcomes. Clinical effectiveness evidence on 
recurrence was taken from a recent meta-analysis of NMIBC with HAL-BLC, costs 
were derived from NHS reference costs, and utilities and disease evolution were 
from the literature. Results: Despite additional treatment and equipment costs, 
base case results suggest that HAL-BLC is a dominant strategy as an adjunct to 
WLC compared to WLC only, when used at initial TURB for patients diagnosed with 
NMIBC. HAL-BLC is expected to be associated with 0.060 incremental QALYs and 
cost-savings of £391 per patient resulting from fewer recurrences and fewer associ-
ated surgical procedures (33 avoided TURBs/149 positively-diagnosed patients), in 
turn due to improved completeness of lesion resection and better tumour staging. 
Probabilistic sensitivity analyses indicated that HAL-BLC was dominant in 91.9% of 
iterations. ConClusions: HAL-BLC as an adjunct to WLC was shown to be a domi-
to assess the uncertainty on the parameters, univariate sensitivity analyses were 
performed. Results: At 100 years, compared to only screening for cervix cancer, 
S2 scenario reduced 73% of the genital warts cases, 92% of the cancer cases in 
women and 87% of the cancer cases in men; while S1 strategy only reduced 56%, 
87% and 63% the cases of the different diseases, respectively. S2 strategy was less 
costly compared with S1: during the first 10 years reduced more than € 25 million 
for the NHS and more than € 282 million over 100 years. The savings over 100 years 
varied between € 141 million and € 1,268 million when considering a 5% or 0% dis-
count, respectively. ConClusions: Vaccinating boys and girls between 11 and 26 
years would significantly reduce the epidemiological and economic burden of HPV 
related diseases in Spain.
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objeCtives: To compare the impact of the quadrivalent (QV) (HPV 6/11/16/18) and 
bivalent (BV) (HPV 16/18) vaccines against HPV in Spain. Methods: A population-
based compartmental dynamic transmission model of HPV developed in the US was 
partially adapted to Spain updating epidemiological data of HPV related diseases, 
the vaccination coverage and direct costs of the diseases. The reduction of the 
number of cases related to HPV and savings associated with the following strategies 
were compared: A) cervix cancer screening (CCS) of women between 25-65 years, 
every 3-5 years and a vaccination program of girls between 11-26 years with the QV 
vaccine; B) CCS+BV vaccine. The analysis was performed from the National Health 
System (NHS) perspective, costs were discounted by 3% and the time horizon was 
100 years. Univariate sensitivity analyses were performed to assess the uncertainty 
on the parameters. Results: At 100 years, considering the current indications of 
the vaccines, lifetime protection against HPV vaccine types and 20 years of cross-
protection, both strategies reduced 208 cases of vulvar and vaginal cancers and 
22,796 cases of CIN2+. The strategy CCS+QV vaccine reduced 18,689 additional cases 
of genital warts due to the protection against 6/11 HPV types, but 4 less cases of 
cervix cancer and 359 less cases of CIN2+ due to better cross-protection of the BV 
vaccine. Nevertheless, savings accumulated during 100 years due to the reduction 
of genital warts cases (€ 215.7 million) compensated the cost associated to cervix 
cancers and CIN2+ that the BV vaccine additionally reduced (€ 3 and € 27.1 mil-
lion, respectively). Therefore, during 100 years the QV vaccine saves € 185.4 million 
more than the BV vaccine. The sensitivity analyses confirmed the stability of the 
results. ConClusions: The QV vaccine provides higher cost savings to the NHS 
compared to the BV vaccine due to the additional efficacy against HPV 6/11 types.
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objeCtives: As with many types of cancer, treatment of multiple myeloma (MM) 
is characterised by sequential treatment lines consisting of innovative expensive 
drugs such as thalidomide, bortezomib and lenalidomide. While cost-effectiveness 
of single treatments has been studied, a full disease model evaluating treatments 
sequentially is currently lacking, consequently, high uncertainty exists on incremen-
tal cost-effectiveness ratios. Therefore, we aimed to take a look at the big picture 
and calculate real-world costs and effects for commonly used treatment pathways 
for MM. Methods: We developed a patient-level simulation (PLS) for elderly (> 65) 
MM patients diagnosed since 2004. Real-world data (N= 621) including patient and 
disease characteristics, treatment information as well as resource use was collected 
from hospital registrations and medical files. Five treatment categories per line 
were observed resulting in 19 commonly used treatment pathways. Parametric 
survival models including patient characteristics such as age, performance sta-
tus, comorbidities and laboratory values were used to predict time to an event, 
i.e. the start of a new treatment or death. Logistic regression determined which of 
the two competing events occurred. The sensitivity of parameters was explored 
through sensitivity analyses. Results: In total, the costs and effects of 19 treat-
ment pathways were calculated. Depending on the treatment sequencing, total 
costs ranged from € 40,810 (Melphalan/Prednison-Thalidomide-Other) to € 132,613 
(Bortezomib-Lenalidomde-Other) while overall survival ranged from 28 to 50 months 
for Bortezomib-Lenalidomide-Thalidomide and Lenalidomide-Bortezomib-Other, 
respectively. Costs per quality-adjusted-life-year (QALY) were between € 21,881 
(Melphalan/Prednison-Thalidomide-Other) and € 57,743 (Bortezomib-Lenalidomide-
Other). Compared to real-world prescription, QALYs could be increased at a cost 
of € 33,785 per QALY (Lenalidomide-Thalidomide-Other). ConClusions: The 
cost-effectiveness of 19 treatment pathways for MM patients was calculated and 
revealed that real-world treatment could be improved at a cost of € 33,785 per QALY. 
Our PLS model proved to be a reliable and robust approach to study entire treat-
ment pathways for MM.
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objeCtives: Non-muscle invasive bladder cancer (NMIBC) is a complex disease 
with wide variation in risks of recurrence and progression, treatment efficacy 
